New therapeutics that modulate chemokine networks

Nature Reviews Drug Discovery

Volumn 1, Issue 5, 2002, Pages 347-358

  Schwarz, Matthias K ^a   Wells, Timothy N C ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYCLOOCTENYLMETHYL) 4 (2,7 DICHLOROXANTHEN 9 YLCARBOXAMIDO) 1 ETHYLPIPERIDINIUM IODIDE; 1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; A 122057; AMD 8664; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTINEOPLASTIC AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR2; CYTOKINE ANTIBODY; DPC 168; DPCA 168; DPCA 37818; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 8 ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEW DRUG; PROTEINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; SB 265610; SCH 350634; SCH 55700; SKF 83589; UNCLASSIFIED DRUG; UNINDEXED DRUG; CC CHEMOKINE RECEPTOR 1; CC CHEMOKINE RECEPTOR 3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ATHEROSCLEROTIC PLAQUE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; IN VITRO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; PHYSIOLOGY;

ANIMALS; CHEMOKINES; HUMANS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-8B;

EID: 0036561677     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd795     Document Type: Review

References (97)

1. Holmes, W. E., Lee, J., Kuang, W. J., Rice, G. C. & Wood, W. I. Structure and functional expression of a human interleukin-8 receptor. Science 253, 1278-1280 (1991).
2. Murphy, P. M. & Tiffany, H. L. Cloning of a complimentary cDNA encoding a functional human interleukin-8 receptor. Science 253, 1280-1283 (1990).
3. Schwartz, T. W. & Rosenkilde, M. M. Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol. Sci. 17, 213-216 (1996).
4. Loetscher, P., Moser, B. & Baggiolini, M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv. Immunol. 74, 127-180 (2000).
5. Proudfoot, A. E. I., Power, C. A. & Wells, T. N. O. The strategy of blocking the chemokine system to combat disease. Immunol. Rev. 177, 246-256 (2000).
6. Gerard, C. & Rollins, B. J. Chemokines and disease. Nature Immunol. 2, 108-115 (2001).
7. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000).
8. Gerard, C. & Rollins, B. J. Chemokines and disease. Nature Immunol. 2, 108-115 (2001).
9. H2-mediated responses. Immunol. Today 19, 568-574 (1998).
10. Lodi, P. J. et al. High-resolution solution structure of the β-chemokine hMIP-1β by multidimensional NMR. Science 263, 1762-1767 (1994).
11. Covell, D. G., Smythers, G. W., Gronenborn, A. M. & Clore, G. M. Analysis of hydrophobicity in the α and β chemokine families and its relevance to dimerization. Protein Sci. 3, 2064-2072 (1994).
12. Neote, K., Mak, J. Y., Kolakowski, L. F. Jr & Schall, T. J. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 84, 44-52 (1994).
13. Kledal, T. N. et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277, 1656-1659 (1997).
14. Weng, Y. et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 273, 18288-18291 (1998).
15. Loetscher, P. et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276, 2986-2991 (2001).
16. Jin, Q. et al. New class of orally bioavailable CXCR2 antagonists. Abstracts of Papers, 221st ACS National Meeting MEDI-258 (2001).
17. White, J. R. et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273, 10095-10098 (1998).
18. Jin, Q. et al. New class of orally bioavailable CXCR2 antagonists. 221st National Meeting of the American Chemical Society Poster, MEDI-258 [online], (cited 08 Apr 02) (2001).
19. Cutshall, N. S., Ursino, R., Kucera, K. A., Latham, J. & Ihle, N. C. Nicotinamide N-oxides as CXCR2 antagonists. Bioorg. Med. Chem. Lett. 11, 1951-1954 (2001).
20. Liang, M. et al. Identification and characterization of potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem. 275, 19000-19008 (2000).
21. Hesselgesser, J. et al. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. 273, 15687-15692 (1998).
22. Ng, H. P. et al. Discovery of novel non-peptide CCR1 receptor antagonists. J. Med. Chem. 42, 4680-4694 (1999).
23. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159, 1701-1710 (2001).
24. Horuk, R. et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol. Lett. 76, 193-201 (2001).
25. Horuk, R. et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. 276, 4199-4204 (2001).
26. Schwarz, M. K. & Wells, T. N. C. Interfering with chemokine networks, the hope for new therapeutics. Curr. Opin. Chem. Biol. 3, 407-417 (1999).
27. Schwarz, M. K. & Wells T. N. C. Recent developments in modulating chemokine networks. Exp. Opin. Ther. Patents 9, 1471-1490 (1999).
28. Anders, H.-J. et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109, 251-259 (2002).
29. Liang, M. et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur. J. Pharmacol. 389, 41-49 (2000).
30. Naya, A. et al. Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem. 44, 1429-1435 (2001).
31. Naya, A. & Saeki, T. J-113863. Drugs Future 26, 121-127 (2001).
32. Fernandez-Botran, R. A small-molecule antagonist of human and murine CCR1 receptors. Expert Opin. Invest. Drugs 10, 1387-1389 (2001).
33. LaRosa, G. Chemokine receptors and drug development: the challenges. British Pharmacological Society Winter Meeting, London, Lecture [online], (cited 08 Apr 02) (2001).
34. Peters, W. & Charo, I. F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr. Opin. Lipidol. 12, 175-180 (2001).
35. Ruth, J. H. et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum. 44, 2750-2760 (2001).
36. Boring, L., Charo, I. F. & Rollins, B. J. in Chemokines in Disease (ed. Hebert, C. A.) 53-65 (Humana, Totowa, New Jersey, 1999).
37. Mirzadegan, T. et al. Identification of the binding site for a novel class of CCR2B chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275, 25562-25571 (2000).
38. Forbes, I. T. et al. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. Bioorg. Med. Chem. Lett. 10, 1803-1806 (2000).
39. Witherington, J. et al. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. Bioorg. Med. Chem. Lett. 11, 2177-2180 (2001).
40. Tarby, C. M. et al. Diamine derivatives as novel antagonists for the CCR2b receptor. Book of Abstracts, 218th ACS National Meeting MEDI-082 (1999).
41. Newton, R. CCR3 as a therapeutic target for asthma and allergic diseases. British Pharmacological Society Winter Meeting, London, Lecture [online], (cited 08 Apr 02) (2001).
42. Harris, R. et al. The discovery of new selective antagonists of CCR3. Inflamm. Res. 49 (Suppl. 2), S101 (2000).
43. Sabroe, I. et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275, 25985-25992 (2000).
44. Naya, A. et al. Discovery of a novel CCR3 selective antagonist. Bioorg. Med. Chem. Lett. 11, 1219-1223 (2001).
45. Saeki, T. et al. Identification of a potent and nonpeptidyl CCR3 antagonist. Biochem. Biophys. Res. Commun. 281, 779-782 (2001).
46. White, J. R. et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J. Biol. Chem. 275, 36626-36631 (2000).
47. Dhanak, D. et al. Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. Bioorg. Med. Chem. Lett. 11, 1441-1444 (2001).
48. Dhanak, D. et al. Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists, Part 2. Bioorg. Med. Chem. Lett. 11, 1445-1450 (2001).
49. Egan, R. W. et al. Effect of SCH 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49, 779-790 (1999).
50. Lacy, P., Weller, P. F. & Moqbel, R. A report from the International Eosinophil Society: eosinophils in a tug of war. J. Allergy Clin. Immunol. 108, 895-900 (2001).
51. Berger, E. A. HIV entry and tropism, the chemokine receptor connection. AIDS 11 (Suppl. A), 3-16 (1997).
52. Michael, N. L. & Moore, J. P. HIV-1 entry inhibitors: evading the issue. Nature Med. 5, 740-742 (1999).
53. Mosier, D. E. et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544-3550 (1999).
54. Trkola, A. et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. USA 99, 395-400 (2002).
55. Palani, A. et al. Discovery of 4-[(Z)-(4- bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem. 44, 3339-3342 (2001).
56. Strizki, J. M. et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 12718-12723 (2001).
57. Tagat, J. R. et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 11, 2143-2146 (2001).
58. Tagat, J. R. et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (SCH-350634), an orally bioavailable, potent CCR5 antagonist. J. Med. Chem. 44, 3343-3346 (2001).
59. Dorn, C. P. et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4- (piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11, 259-264 (2001).
60. Finke, P. E. et al. Antagonists of the human CCR5 receptor as anti-HIV 1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N- (phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11, 265-270 (2001).
61. Finke, P. E. et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N- (phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin- 1-yl]butanes. Bioorg. Med. Chem. Lett. 11, 2469-2473 (2001).
62. Finke, P. E. et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2- (phenyl)-4-(4-(N-(alkyl)-N (benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11, 2475-2479 (2001).
63. Kim, D. et al. Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg. Med. Chem. Lett. 11, 3103-3106 (2001).
64. Kim, D. et al. Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg. Med. Chem. Lett. 11, 3099-3102 (2001).
65. Hale, J. J. et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg. Med. Chem. Lett. 11, 1437-1440 (2001).
66. Hale, J. J. et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg. Med. Chem. Lett. 11, 2741-2745 (2001).
67. Shah, S. K. Synthesis and evaluation of CCR5 antagonists containing modified 4-(piperidin-1-yl)-2- phenyl-1-(phenylsulfonylamino)-butane. Abstracts of Papers, 222nd ACS National Meeting MEDI-105 (2001).
68. Willoughby, C. A. et al. Combinatorial synthesis of CCR5 antagonists. Bioorg. Med. Chem. Lett. 11, 3137-3141 (2001).
69. Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 96, 5698-5703 (1999).
70. Shiraishi M. et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem. 43, 2049-2063 (2000).
71. Takashima, K. et al. Inhibitory effects of small-molecule CCR5 antagonists on human Immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob. Agents Chemother. 45, 3538-3543 (2001).
72. Maeda, K. et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276, 35194-36200 (2001).
73. Schols, D. et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186, 1383-1388 (1997).
74. Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72-77 (1998).
75. Bridger, G. J. et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bisazamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J. Med. Chem. 42, 3971-3981 (1999).
76. Hendrix, C. W. et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44, 1667-1673 (2000).
77. MacFarlane, R. T. et al. An orally bioavailable CXCR4 antagonist for inhibition of HIV replication. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Poster, 1845 [online], (cited 08 Apr 02) (2000).
78. Matthys, P. et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J. Immunol. 167, 4686-4692 (2001).
79. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
80. Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G. & Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961-4965 (2001).
81. Hunter, M. G. et al. BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood, 86, 4400-4408 (1995).
82. Clemons, M. J. et al. A randomized Phase-II study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. Blood 92, 1532-1540 (1998).
83. Kruse, N., Tony, H. P. & Sebald, W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. 11, 3237-3244 (1992).
84. McKinnon, M. et al. An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J. Exp. Med. 186, 121-129 (1997).
85. 2-terminal residues. J. Exp. Med. 181, 631-640 (1995).
86. Gong, J. H., Uguccioni, M., Dewald, B., Baggiolini, M. & Clark-Lewis, I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J. Biol. Chem. 271, 10521-10527 (1996).
87. Gong, J. H., Ratkay, L. G., Waterfield, J. D. & Clark-Lewis, I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-Ipr mouse model. J. Exp. Med. 186, 131-137 (1997).
88. Zhang, Y. J., Rutledge, B. J. & Hollins, B. J. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J. Biol. Chem. 269, 15918-15924 (1994).
89. Proudfoot, A. E. I. et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271, 2599-2603 (1996).
90. Simmons, G. et al. Sensitive inhibition of primary HIV-1 strains in macrophages and lymphocytes by a CCR5 antagonist derived by chemical modification of RANTES at the N-terminus. Science 276, 276-279 (1997).
91. Kinter, A. et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc. Natl Acad. Sci. USA 95, 11880-11885 (1998).
92. Mack, M. et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215-1224 (1998).
93. Domine, D. High-throughput lead discovery using predictive substructural analysis. Abstracts of Papers, 221st ACS National Meeting COMP-099 (2001).
94. Palovich, M. R. Discovery and characterization of a novel series of potent CXCR2 antagonists with improved in vivo activity. Book of Abstracts, 219th ACS National Meeting MEDI-338 (2000).
95. Widdowson, K. et al. The role of the anionic groups in the receptor binding of interleukin-8 antagonists. Lett. Pept. Sci. 5, 235-239 (1998).
96. Auten, R. L. et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J. Pharmacol. Exp. Ther. 299, 90-95 (2001).
97. Domine, D., Colinge, J. & Church, D. High-throughput lead discovery using predictive substructural analysis. 221st National Meeting of the American Chemical Society, San Diego, Lecture, COMP-099 [online], (cited 08 Apr 02) (2001).